Browse Articles

Discover research articles across all indexed journals

Structural predictability differences in long-term regional crop yield modeling with climate and area signals

Scientific Reports Munire Muhetaer, Jing Zhu, Gulizada Haisa et al. Jul 13, 2026 DOI: 10.1038/s41598-026-58313-4

Abstract Climate-driven crop yield modeling has been widely studied; however, the marginal predictive value of climate signals relative to temporal persistence remains insufficiently examined at the annual regional scale. This study investigates structural differences in long-term yield predictability using anonymized multi-region panel data spanning 2000–2023. A pooled one-step-ahead machine learning forecasting framework was constructed and evaluated against a naïve persistence baseline to assess the additional contribution of climate and area signals. Results reveal clear crop-specific heterogeneity. For cotton, climate-only models provide limited predictive skill, whereas incorporating planting area substantially improves performance, achieving a test R 2 of approximately 0.72, comparable to the persistence baseline (R 2 = 0.71). In contrast, wheat exhibits persistence-dominated predictability in the pooled dataset, with the persistence model achieving a test R 2 of 0.99. Additional analyses revealed that this high predictive performance is primarily associated with stable between-region differences rather than exceptionally strong within-region temporal persistence. These findings suggest that annual regional yield predictability is strongly crop-dependent and may be constrained by the temporal stability of the production system. Climate signals alone were insufficient to outperform persistence under the annual aggregation setting used in this study. Persistence may account for a large proportion of predictable variation in highly stable crop systems. However, these results should be interpreted as scale- and data-specific evidence rather than as a definitive assessment of climate-driven yield predictability. The findings highlight the importance of persistence-aware evaluation and careful benchmark design in agricultural forecasting research.

Role of conducting filler on electromagnetic shielding performance of CaCu3Ti4O12/CoFe2O4/Al/silicone composites over wide frequency range

Scientific Reports Neelam Kumari, Amena Salim, Rahul Singhal et al. Jul 13, 2026 DOI: 10.1038/s41598-026-47903-x

Extraction and structural characterization of functional β-glucan from Wuping Ganoderma sinense and its immunomodulatory activity on mouse Raw 264.7 macrophages

Scientific Reports Biaosheng Lin, Ping Li, Jing Li et al. Jul 13, 2026 DOI: 10.1038/s41598-026-61555-x

Charlson comorbidity index predicts treatment tolerance and survival in non-small cell lung cancer: a multivariable retrospective study

Scientific Reports Kai Ling, Wei Bao, Zhe Wang Jul 13, 2026 DOI: 10.1038/s41598-026-62089-y

Advanced beneficiation of quartz ore for high-purity silica production

Scientific Reports Mostafa Chegini Jul 13, 2026 DOI: 10.1038/s41598-026-61714-0

Direct δ‐Lactone Synthesis From Free Alcohols via Photoinduced δ‐C(sp <sup>3</sup> )–H Carbonylation in Flow

Angewandte Chemie International Edition Prakash Chandra Tiwari, Runkang Liu, Timothy Noël Jul 13, 2026 DOI: 10.1002/anie.5570038

ABSTRACT The direct carbonylation of unactivated C(sp 3 )─H bonds remains a fundamental challenge in synthesis. Herein, we report a photo‐flow strategy for the δ‐C(sp 3 )─H carbonylative lactonization of free alcohols using carbon monoxide. The transformation proceeds via photochemical generation of alkoxyl radicals, selective 1,5‐hydrogen atom transfer, CO trapping to form δ‐acyl radicals, and a crucial radical–polar crossover event that enables intramolecular cyclization to δ‐lactones. The use of a strongly oxidizing acridinium photocatalyst is essential to promote acyl radical oxidation, distinguishing this manifold from conventional proton‐coupled electron transfer (PCET) or ligand‐to‐metal charge transfer (LMCT) pathways. Continuous‐flow conditions facilitate efficient gas–liquid mass transfer and safe handling of CO, enabling short reaction times and scalability. The method tolerates diverse functional groups and provides direct access to structurally complex and bioactive δ‐lactone motifs from simple alcohol feedstocks.

A Non‐Covalent [4Fe–4S]/[2Fe] Interface in HydF Guides [FeFe]‐Hydrogenase Maturation

Angewandte Chemie International Edition Giorgio Caserta, Princess R. Cabotaje, Armel T. Waffo et al. Jul 13, 2026 DOI: 10.1002/anie.8078898

ABSTRACT Maturation of [FeFe]‐hydrogenase depends on the HydF maturase, a [4Fe–4S]‐containing scaffold protein that assembles and delivers the organometallic [2Fe] subsite of the H‐cluster. Despite extensive research, the function of the HydF [4Fe–4S] cluster and its interaction with the [2Fe] cofactor remains unresolved, with conflicting evidence regarding cyanide linkage isomerism and the functional role of the cubane. Using 57 Fe nuclear resonance vibrational spectroscopy in combination with selective isotopic labeling, we show that the [2Fe] subsite binds adjacent to the [4Fe–4S] cluster without forming a covalent cyanide bridge, while remaining electronically coupled. Complementary protein structure predictions support this arrangement and reconcile prior spectroscopic, mutagenesis, and structural studies. Extending this framework to earlier biosynthetic steps, additional structure predictions suggest that the [4Fe–4S] cluster contributes to assembly of the CH 2 –NH–CH 2 bridge of the [2Fe] site via interactions with the lipoate cofactor of the aminomethyl‐lipoyl H‐protein, thereby positioning reactive components in proximity to the [2Fe] precursor. Together, these results provide a coherent structural and mechanistic framework for HydF function across distinct stages of H‐cluster biosynthesis.

Polarity‐Directed Synthesis of an Exfoliable 2D Polyoxometalate‐Based Metal‐Organic Framework for Noble Metal‐Free Alkyne Transfer Semi‐Hydrogenation

Angewandte Chemie International Edition Xusheng Dai, Yalei Zhang, Yue Zhao et al. Jul 13, 2026 DOI: 10.1002/anie.7007153

ABSTRACT Two‐dimensional polyoxometalate‐based metal–organic frameworks (2D POMOFs) hold great promise for catalysis, yet their directed synthesis and facile exfoliation remain challenging. Herein, we report the rational assembly of an exfoliable 2D POMOF, H 5 [(Co(H 2 O) 2 ) 2 (C 18 H 12 N 6 ) 4 (P 2 W 15 Ta 3 O 62 )]·18H 2 O ( 1 ), directed by the nonuniform charge distribution within the POM. The unique layered structure enables a multi‐step morphological control strategy: hydrothermal synthesis gives access to high‐quality single crystals, while a scalable bulk synthesis allows the rapid production of nanobelts, which can subsequently be exfoliated into ultrathin bilayer nanosheets via a liquid‐nitrogen treatment, or even monolayer nanosheets via solvent‐assisted sonication. The bilayer nanosheets exhibit high catalytic activity and selectivity for alkyne transfer semi‐hydrogenation, outperforming the corresponding bulk and nanocrystalline counterparts and rivaling noble‐metal‐based catalysts. This work establishes charge‐asymmetric POM‐directed synthesis as a viable strategy for creating defined 2D materials.

Author Correction: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours

Nature Luojia Yang, Paul A. Renauer, Kaiyuan Tang et al. Jul 13, 2026 DOI: 10.1038/s41586-026-10855-3

This microbiologist endured a four-year court battle over COVID-19 tests

Nature Anne Gulland Jul 13, 2026 DOI: 10.1038/d41586-026-01654-x

A Thermally Stable and Processable [4 + 2] Photodimer of π-Extended Anthracene as an Optical Force Probe for Damage Detection in Thermoplastics

Journal of the American Chemical Society Sonja Storch, David Wienen, Regina Lennarz et al. Jul 13, 2026 DOI: 10.1021/jacs.6c05379

How voluntary work can boost your career in science

Nature Jacqui Thornton Jul 13, 2026 DOI: 10.1038/d41586-026-01339-5

Perovskite–organic tandem solar cells with a photo-transformable stabilizer

Nature Ruihan Wu, Shucheng Qin, Tianwei Zou et al. Jul 13, 2026 DOI: 10.1038/s41586-026-10869-x

Daily briefing: The rise of evidence-based medicine

Nature Flora Graham Jul 13, 2026 DOI: 10.1038/d41586-026-02206-z

Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial

Journal of Clinical Oncology Hanny Al-Samkari, Joseph J. Shatzel, Sandhya R. Panch et al. Jul 13, 2026 DOI: 10.1200/jco-26-00568

PURPOSE Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available approved treatment. Avatrombopag is a potent, second-generation oral thrombopoietin receptor agonist promising for CIT management. METHODS We conducted a multicenter, randomized, double-blind, investigator-initiated US trial of avatrombopag or placebo (1:1) in GI cancer patients with persistent CIT (platelets ≤85 × 10 9 /L on day 1 of a chemotherapy cycle despite adequate time to recover from the prior cycle). The primary end point was successful correction of CIT and prevention of recurrence (defined as recovery of platelets to ≥100 × 10 9 /L, no chemotherapy dose modification/delay, and prevention of CIT recurrence [platelets ≥100 × 109/L] at end of the on-study cycle). RESULTS The trial was closed to enrollment by the data and safety monitoring board at the planned interim analysis after meeting prespecified stopping criteria for efficacy. Sixteen of 23 patients (70% [95% CI, 47 to 87]) receiving avatrombopag achieved the primary end point versus 4/24 patients (17% [95% CI, 5 to 37]) receiving placebo ( Z = 3.67, P &lt; .001). The median (IQR) platelet count at the end of the on-cycle treatment period was 157 (136-202) × 10 9 /L with avatrombopag versus 72 (68-134) × 10 9 /L with placebo. Adverse events (AEs) and serious AEs occurred in 78% and 17% of patients receiving avatrombopag and 46% and 0% of patients receiving placebo, respectively. No serious AEs were study drug-related. There were no treatment-related AEs leading to death or discontinuation of study drug. CONCLUSION In this randomized, placebo-controlled trial, avatrombopag was efficacious in the management of persistent CIT in patients with GI cancers. These findings are promising for a common, challenging oncologic complication that prevents delivery of full-dose, on-time, cancer-directed therapy.

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study

Journal of Clinical Oncology David A. Sallman, Guillermo Garcia-Manero, Naval Daver et al. Jul 13, 2026 DOI: 10.1200/jco-25-00617

PURPOSE To evaluate the efficacy and safety of the cluster of differentiation 47–targeted antibody magrolimab plus azacitidine (Magro/Aza) versus azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS) in the phase III ENHANCE study (ClinicalTrials.gov identifier: NCT04313881 ). METHODS Based on the Revised International Prognostic Scoring System, patients with intermediate- to very-high-risk MDS were randomly assigned to receive Magro (1 mg/kg on days [D]1 and 4; 15 mg/kg on D8; 30 mg/kg on D11 and D15, and then once per week for five doses, followed by 30 mg/kg maintenance doses once every 2 weeks)/Aza (75 mg/m 2 daily on D1-7 or on D1-5 and 8-9 in 28-day cycles) or matched placebo plus azacitidine (Placebo/Aza). Dual primary end points were complete remission (CR) rate (per 2006 International Working Group criteria) and overall survival (OS). RESULTS At final analysis, 539 patients were randomly assigned to Magro/Aza (n = 268) or Placebo/Aza (n = 271) arms. Baseline characteristics were generally well balanced between treatment arms. In the Magro/Aza versus Placebo/Aza arms, the CR rate was 21.3% versus 23.6% (odds ratio, 0.876 [95% CI, 0.585 to 1.312]; P = .5218), and median OS was 15.9 versus 18.6 months (hazard ratio, 1.203 [95% CI, 0.947 to 1.528]; P = .1299). Magro/Aza had a higher incidence of grade ≥3 adverse events (AEs; 92.8% v 79.2%), AE-associated study drug discontinuations (24.0% v 12.1%), serious AEs (71.9% v 51.5%), and fatal AEs (15.2% v 9.8%) versus Placebo/Aza. CONCLUSION ENHANCE did not meet the primary end points of CR rate and OS, and showed more frequent severe AEs in patients treated in the Magro/Aza arm.

Outside Front Cover: Triplet–Triplet Annihilation Upconversion Circularly Polarized Luminescence That Originates From Achiral and Racemic Luminophores Encapsulated in Chiral Silica (Angew. Chem. Int. Ed. 29/2026)

Angewandte Chemie International Edition Shunsuke Morii, Himawari Kunitake, Yasumasa Miyoshi et al. Jul 13, 2026 DOI: 10.1002/anie.2026-m2506052100

Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape

Journal of Clinical Oncology Marla Lipsyc-Sharf, Sara A. Hurvitz Jul 13, 2026 DOI: 10.1200/jco-26-00672

Over the past three decades, the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone a remarkable transformation. Once associated with poor outcomes and a median survival of &lt;2 years in the metastatic setting, HER2-positive metastatic breast cancer is at present increasingly managed for years, with long-term survival beyond 5 years becoming common. Parallel advances in early-stage therapy have substantially reduced recurrence rates and altered the clinical landscape of metastatic disease, with a growing proportion of patients currently presenting with de novo metastatic disease rather than relapse after prior HER2-directed treatment. These improvements have been driven by successive generations of HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. Most recently, trastuzumab deruxtecan (T-DXd) has demonstrated unprecedented efficacy and is rapidly moving earlier in treatment algorithms across both metastatic and curative-intent settings. This shift raises important questions regarding optimal sequencing, toxicity management—particularly for interstitial lung disease—and the downstream implications for other HER2-directed therapies. In this review, we summarize the evolution of HER2-targeted therapy and discuss strategies for managing HER2-positive breast cancer across disease stages in the era of earlier treatment with T-DXd.

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0

Journal of Clinical Oncology Jamie L. Lesnock, Sarah Temin, Sara Bouberhan et al. Jul 13, 2026 DOI: 10.1200/jco-26-01591

PURPOSE To provide guidance regarding the systemic treatment of patients with high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) experiencing recurrence. METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS 819 publications were identified in the literature search. After applying the eligibility criteria, 147 publications of RCTs and systematic reviews comprising the entire body of evidence remained, forming the evidentiary basis, of which 36 directly informed the guideline recommendations. RECOMMENDATIONS For patients with recurrent platinum-sensitive EOC, clinicians should offer platinum-based combination regimens, specifically pegylated liposomal doxorubicin (PLD) plus carboplatin, paclitaxel plus carboplatin, or gemcitabine plus carboplatin. Bevacizumab may be added to a platinum-based doublet followed by bevacizumab maintenance. For patients who are not candidates for platinum-based therapy, clinicians may utilize recommendations for first-line treatment of patients with relapsed platinum-resistant disease. For patients with platinum-resistant or refractory EOC high-grade disease and validated folate receptor alpha (FRα) expression, mirvetuximab soravtansine is strongly recommended. Other recommended systemic options for this population include PLD monotherapy, paclitaxel (once weekly or once every three weeks), bevacizumab in combination with chemotherapy, or the combination of relacorilant and nab-paclitaxel; gemcitabine monotherapy remains a conditional alternative. Regarding surgical interventions, there is currently insufficient evidence to recommend secondary cytoreduction or hyperthermic intraperitoneal chemotherapy. Clinicians may discuss secondary cytoreduction for platinum-sensitive recurrences where complete gross resection is highly achievable. Post-treatment monitoring and specialty survivorship care should be offered on a case-by-case basis, potentially including physical exams, biochemical testing, and imaging. There is insufficient data to recommend one combination versus another. Additional information is available on the ASCO Publications website .

Inside Front Cover: Covalently Hydrophobic Nanocarbon Supported Ni Single‐Atom Catalysts for Highly Selective CO <sub>2</sub> Electroreduction (Angew. Chem. Int. Ed. 29/2026)

Angewandte Chemie International Edition Yanzheng Ji, Huaizhu Wang, Yuxiao Meng et al. Jul 13, 2026 DOI: 10.1002/anie.2026-m2506061700